Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Decrease in Short Interest

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) was the target of a significant decrease in short interest in April. As of April 15th, there was short interest totalling 2,500,000 shares, a decrease of 10.7% from the March 31st total of 2,800,000 shares. Based on an average daily trading volume, of 836,100 shares, the days-to-cover ratio is presently 3.0 days.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Cantor Fitzgerald reissued a "neutral" rating and set a $165.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. The Goldman Sachs Group downgraded Alnylam Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their target price for the stock from $230.00 to $173.00 in a research note on Friday, February 16th. BMO Capital Markets reaffirmed an "outperform" rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. Chardan Capital cut their price objective on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a "buy" rating on the stock in a research report on Friday, February 16th. Finally, Wells Fargo & Company decreased their target price on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an "equal weight" rating for the company in a research report on Friday, February 16th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $215.88.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ALNY. Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company's stock valued at $2,286,181,000 after purchasing an additional 287,064 shares during the period. Wellington Management Group LLP increased its stake in Alnylam Pharmaceuticals by 6.0% in the 3rd quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company's stock worth $1,139,074,000 after acquiring an additional 364,021 shares during the last quarter. Capital International Investors raised its holdings in shares of Alnylam Pharmaceuticals by 15.8% in the 4th quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company's stock valued at $686,641,000 after acquiring an additional 488,814 shares in the last quarter. Capital Research Global Investors boosted its position in shares of Alnylam Pharmaceuticals by 5.3% during the 4th quarter. Capital Research Global Investors now owns 2,930,079 shares of the biopharmaceutical company's stock valued at $560,880,000 after acquiring an additional 146,236 shares during the last quarter. Finally, Norges Bank purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $390,438,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY traded up $4.05 on Monday, reaching $147.36. 439,847 shares of the company's stock were exchanged, compared to its average volume of 772,379. The firm has a market cap of $18.56 billion, a price-to-earnings ratio of -41.17 and a beta of 0.39. The stock has a fifty day simple moving average of $150.21 and a 200-day simple moving average of $165.76. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to analysts' expectations of $439.38 million. The company's revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.68) EPS. As a group, sell-side analysts predict that Alnylam Pharmaceuticals will post -4.46 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.